Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas

Journal of Neuro-Oncology

Volumn 92, Issue 1, 2009, Pages 1-6

  Sioka, Chrissa ^a,b   Kyritsis, Athanassios P ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Chemotherapy; Hydroxyurea; Interferon; Meningioma; Progesterone

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BUSULFAN; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DILTIAZEM; DOXORUBICIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IRINOTECAN; MEPITIOSTANE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MEVINOLIN; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN 1; OCTREOTIDE; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; VERAPAMIL;

ADD ON THERAPY; BLOOD TOXICITY; BRAIN SURGERY; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; MENINGIOMA; MULTIPLE CYCLE TREATMENT; PERITONEUM CANCER; PLOIDY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 59349089497     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9734-y     Document Type: Review

References (43)

1. Kaba SE, Kyritsis AP (2006) Atypical and malignant meningiomas. In: Raghavan D, Brecher ML, Johnson DH, Metopol NJ, Moots PL, Rose P (eds) Textbook of uncommon cancer. John Wiley & Sons, West Sussex, England, pp. 303-314
2. Kyritsis AP (1996) Chemotherapy for meningiomas. J Neurooncol 29:269-272. doi: 10.1007/BF00165657
3. Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21-27
4. Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y (2007) A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene. Gan To Kagaku Ryoho 34:265-268
5. Buccoliero AM, Castiglione F, Degl'Innocenti DR, Arganini L, Taddei A, Ammannati F, Mennonna P, Taddei GL (2007) Cyclooxygenase-2 (COX-2) overexpression in meningiomas: Real time PCR and immunohistochemistry. Appl Immunohistochem Mol Morphol 15:187-192. doi: 10.1097/ 01.pai.0000201807.58801.fc
6. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103(3):508-517
7. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2007) Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109:588-597. doi: 10.1002/cncr.22441
8. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS (2002) Lovastatin is a potent inhibitor of meningioma cell proliferation: Evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56:133-142. doi: 10.1023/A:1014588214966
9. Braun B, Lange M, Oeckler R, Mueller MM (2004) Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 68:131-140. doi: 10.1023/ B:NEON.0000027751.87894.f0
10. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD (2008) Evaluation of meningioma aggressiveness by (99 m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg 110:645-648. doi: 10.1016/j.clineuro.2008.03.016
11. Alexiou GA, Tsiouris S, Goussia A, Polyzoidis KS, Fotopoulos AD, Kyritsis AP (2008) (99 m)Tc-Tetrofosmin SPECT for the assessment of meningioma malignancy. J Clin Neurosci 15:721-722. doi: 10.1016/ j.jocn.2007.08.031
12. Chamberlain MC, Glantz MJ (2005) Cerebrospinal fluid-disseminated meningioma. Cancer 103:1427-1430. doi: 10.1002/cncr.20926
13. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840-844
14. Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165-170. doi: 10.1023/A:1026770624783
15. Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: Enlarged cohort with extended follow-up. Br J Neurosurg 18:495-499
16. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341-346
17. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221-226. doi: 10.1023/ B:NEON.0000021827.85754.8e
18. Weston GJ, Martin AJ, Mufti GJ, Strong AJ, Gleeson MJ (2006) Hydroxyurea treatment of meningiomas: A pilot study. Skull Base 16:157-160. doi: 10.1055/s-2006-949518
19. Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Metellus P, Barrie-Attarian M, Grisoli F (2004). Hydroxyurea treatment for unresectable meningioma Neurochirurgie 50:461-467. doi: 10.1016/ S0028-3770(04)98326-9
20. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: Results of a pilot study. J Neurooncol 74:157-165. doi: 10.1007/s11060-004-2337-3
21. Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC, Hofman FM, Schonthal AH, Chen TC (2007) Irinotecan: A potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 106:455-462. doi: 10.3171/jns.2007.106.3.455
22. Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78:271-276. doi: 10.1007/ s11060-005-9093-x
23. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865-1874
24. Prat R, Banzo J, Diaz FJ (1997). Somatostatin receptors in meningioma: diagnostic and therapeutic value. Rev Neurol 25:2002-2005
25. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155-166. doi: 10.1023/B:NEON.0000013498.19981.55
26. Kunert-Radek J, Stepien H, Radek A, Pawlikowski M (1987) Somatostatin suppression of meningioma cell proliferation in vitro. Acta Neurol Scand 75:434-436
27. Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, Reubi JC (1992) Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74:543-547. doi: 10.1210/jc.74.3.543
28. Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue. Neurology 69:969-973. doi: 10.1212/01.wnl.0000271382.62776.b7
29. Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJ, Bergstrom M, Lamberts SW (1991) Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 27:416-419
30. Wober-Bingol C, Wober C, Marosi C, Prayer D (1995) Interferon-alfa-2b for meningioma. Lancet 345:331. doi: 10.1016/S0140-6736(95)90326-7
31. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271-275. doi: 10.1097/ 00006123-199702000-00007
32. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 7:2269-2276
33. Huisman TW, Tanghe HL, Koper JW, Reubi JC, Foekens JA, Avezaat CJ, Braakman R, Lamberts SW (1991) Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer 27:1453-1457
34. Grunberg SM (1994) Role of antiprogestational therapy for meningiomas. Hum Reprod 9(suppl 1):202-207
35. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861-866
36. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H (1992) Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:486-490
37. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727-733. doi: 10.1080/07357900601062339
38. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. J Neurooncol 15:75-77. doi: 10.1007/BF01050266
39. Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Masuo O, Naito Y (2000) Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report. J Neurosurg 93:132-135
40. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD (1995) In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 36:365-373. doi: 10.1097/ 00006123-199502000-00017
41. Jensen RL, Petr M, Wurster RD (2000) Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 46:692-702. doi: 10.1097/ 00006123-200003000-00032
42. Ragel BT, Gillespie DL, Kushnir V, Polevaya N, Kelly D, Jensen RL (2006) Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery 59:1109-1120. doi: 10.1227/01.NEU.0000232864.73007.38
43. Ragel BT, Couldwell WT, Wurster RD, Jensen RL (2007) Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus 23(4):E10